River BioMedics develops a pipeline of small molecule drugs for cardiac diseases. We directly target the heart muscle to effect key biological processes in the pathology of cardiac diseases. We have currently selected three (undisclosed) targets for the development of our lead candidates. By using our 3D human cardiac in vitro models for target and compound validation, we create a human relevant drug pipeline.